Surya Kant Kalauni
University of Toyama
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Surya Kant Kalauni.
Cancer Research | 2006
Suresh Awale; Jie Lu; Surya Kant Kalauni; Yukiko Kurashima; Yasuhiro Tezuka; Shigetoshi Kadota; Hiroyasu Esumi
Tumor cells generally proliferate rapidly and the demand for essential nutrients as well as oxygen always exceeds the supply due to the unregulated growth and the insufficient and inappropriate vascular supply. However, cancer cells show an inherent ability to tolerate extreme conditions, such as that characterized by low nutrient and oxygen supply, by modulating their energy metabolism. Thus, targeting nutrient-deprived cancer cells may be a novel strategy in anticancer drug development. Based on that, we established a novel screening method to discover anticancer agents that preferentially inhibit cancer cell viability under the nutrient-deprived condition. After screening 500 medicinal plant extracts used in Japanese Kampo medicine, we found that a CH(2)Cl(2)-soluble extract of Arctium lappa exhibited 100% preferential cytotoxicity under the nutrient-deprived condition at a concentration of 50 microg/mL with virtually no cytotoxicity under nutrient-rich condition. Further bioassay-guided fractionation and isolation led to the isolation of arctigenin as the primary compound responsible for such preferential cytotoxicity; the compound exhibited 100% preferential cytotoxicity against nutrient-deprived cells at a concentration of 0.01 microg/mL. Furthermore, arctigenin was also found to strongly suppress the PANC-1 tumor growth in nude mice, as well as the growth of several of the tested pancreatic cancer cell lines, suggesting the feasibility of this novel antiausterity approach in cancer therapy. Further investigation of the mechanism of action of arctigenin revealed that the compound blocked the activation of Akt induced by glucose starvation, which is a key process in the tolerance exhibited by cancer cells to glucose starvation.
Tetrahedron Letters | 2003
Arjun H. Banskota; Faisal Attamimi; Tepy Usia; Thein Zaw Linn; Yasuhiro Tezuka; Surya Kant Kalauni; Shigetoshi Kadota
Three novel norcassane-type diterpenes were isolated from a CH2Cl2 extract of the seed kernels of Caesalpinia crista together with four known cassane-type diterpenes. All the new compounds represent unprecedented carbon framework. Norcaesalpinin A (1) and B (2) had 17-norcassane skeleton, while norcaesalpinin C (3) had 16-norcassane skeleton. Their structures were elucidated on the basis of spectral analysis.
Biochemistry & Pharmacology: Open Access | 2015
Khaga Raj Sharma; Achyut Adhikari; Almas Jabeen; Nida Dastagir; Surya Kant Kalauni; M. Iqbal Choudhary; Yuba Raj Pokharel
Glutinone (1), coixol (2), friedelin (3), glutinol (4), and betulinic acid (5) were isolated from the plant Scoparia dulcis. Their structures were identified using mass and 1D- and 2D- NMR techniques. All the compounds were tested for their immunomodulatory potential in oxidative burst assay. Compound 1 showed a significant inhibitory effect on the release of reactive oxygen species (ROS) from zymosan activated cells from whole blood (IC50 = 4.3 ± 0.6 μg/mL) as well as from isolated PMNs (IC50 = 5.0 ± 0.3 μg/mL) as compared to standard drug ibuprofen in whole blood (IC50 = 11.2± 1.9 μg/ mL) and in isolated PMNs (IC50 = 2.5± 0.6 μg/mL) shows that it is more active in whole blood as compared with isolated PMNs. Compound 1 when further tested for its effect on pro-inflammatory cytokines TNF-α, IL-1β and on nitric oxide (NO), was found to moderately inhibiting the production of TNF-α (19%) at a concentration 25 μg/mL. On the other hand a weak inhibitory effect of this compound was also observed on the production of IL-1β and NO production, whereas, compounds 2-5 showed no effect (IC50 = >100) on the release of ROS from zymosan activated cells.
Journal of Natural Products | 2005
Thein Zaw Linn; Suresh Awale; Yasuhiro Tezuka; Arjun H. Banskota; Surya Kant Kalauni; Faisal Attamimi; Jun-ya Ueda; Puji Budi Setia Asih; Din Syafruddin; Ken Tanaka; Shigetoshi Kadota
Biological & Pharmaceutical Bulletin | 2006
Surya Kant Kalauni; Suresh Awale; Yasuhiro Tezuka; Arjun H. Banskota; Thein Zaw Linn; Puji Budi Setia Asih; Din Syafruddin; Shigetoshi Kadota
Bioorganic & Medicinal Chemistry Letters | 2006
Suresh Awale; Eduardo Massao N. Nakashima; Surya Kant Kalauni; Yasuhiro Tezuka; Yukiko Kurashima; Jie Lu; Hiroyasu Esumi; Shigetoshi Kadota
Journal of Natural Medicines | 2007
Aty Widyawaruyanti; Subehan; Surya Kant Kalauni; Suresh Awale; Maria Nindatu; Noor Cholies Zaini; Din Syafruddin; Puji Budi Setia Asih; Yasuhiro Tezuka; Shigetoshi Kadota
Chemical & Pharmaceutical Bulletin | 2005
Surya Kant Kalauni; Suresh Awale; Yasuhiro Tezuka; Arjun H. Banskota; Thein Zaw Linn; Shigetoshi Kadota
Journal of Natural Products | 2004
Surya Kant Kalauni; Suresh Awale; Yasuhiro Tezuka; Arjun H. Banskota; Thein Zaw Linn; Shigetoshi Kadota
Chemical & Pharmaceutical Bulletin | 2006
Suresh Awale; Thein Zaw Linn; Yasuhiro Tezuka; Surya Kant Kalauni; Arjun H. Banskota; Faisal Attamimi; Jun-ya Ueda; Shigetoshi Kadota